Unbiased Analysis of Today's Healthcare Issues
To find out the answer to this question, check out a live webinar on Wednesday, March 13th at 1:30pm EDT led by Dr. Anupam Jena, MD, PhD. Dr. Jena is a Harvard Professor and Precision Health Economics Scientific Advisor. In this unique one-hour webinar, Dr. Jena will outline a broader framework for assessing value to improve identification of not…
That is the question of interest of a new study by Snider et al. (2018) in Value in Health. The authors use six reviews by the Institute for Clinical and Economic Review (ICER) that forecast the likely national spend on specific drugs or drug classes as case studies. Their study compares these forecast to subsequent…
That is the question asked by Peter Neumann, Madison Silver, and Joshua T. Cohen in their recent Health Affairs blog article. The authors use publicly-available information from ICER reports, in order to analyze committee member votes across 48 treatments assessed by ICER. ICER reports considered were published between December 2014 and August 2018. As shown…
The Second Panel on Cost Effectiveness in Health and Medicine made a number of recommendations of how to improve cost effectiveness analysis (CEA). Yet, CEA is far from “solved”. In a recent article by Neumann et al. (2018), the Second Panel identifies seven CEA areas where additional research is needed. This include: CEA and perspective:…
What happens when you have missing data? Many people recommend using multiple imputation (see Briggs et al. 2003; Faria et al. 2014; Gomes et al. 2013; Hunter et al., 2015; Hughes et al., 2016). This approach, however, generally assumes that data are missing at random. Missing at random could be interpreted as the probability that health…
Value frameworks are all the rage of late. But are payers really using them? According to my colleague Jeremy Schafer, the answer is yes. From an article in Drug Topics: “Value assessment may become more important as the health-care market shifts to outcomes and value-based reimbursement models,” said Jeremy Schafer, PharmD, MBA, Senior Vice President…
That is the topic of a Health Affairs blog post published today by James Baumgarder and Peter Neumann. An excerpt is below. Cost-effectiveness analysis (CEA) is an important tool for assessing and pointing the way toward better health care efficiency. The number of published CEAs on health care interventions has blossomed, averaging 34 per year…
High drug prices are in the spotlight. While expensive, many of these treatments improve patients quality of life and even extend patient’s life expectancy. How do you balance treatment cost and benefits? Peter Neumann and Gillian Sanders have a perspective piece in NEJM describing the findings of the Second Panel on Cost-Effectiveness in Health and…
Value-based pricing has become all the rage of late among health policy wonks. Medicare aims to tie 90% of reimbursement to some measure of value by 2018. The AMA has endorsed value-based pricing for pharmaceuticals. Organizations such as IVI and ICER propose different approaches for measuring value as well. Typically, value is measured as the…
How do you do cost effectiveness the right way? Peter Neumann–a colleague of mine at Precision Health Economics–edits a book to explain how to do just that. Neumann and Gillian D. Sanders, Louise B. Russell, Joanna E. Siegel, and Theodore G. Ganiats have produced a second edition of their classic text Cost-Effectiveness in Health and Medicine. The…